Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Podosophia 4/2018

23-11-2018 | Oncologie

Voetproblematiek bij een oncologisch behandeltraject

De rol van de podotherapeut bij de oncologische voet

Auteurs: Petra Renders, MSc Donja Lansink

Gepubliceerd in: Podosophia | Uitgave 4/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Het aantal mensen met kanker neemt toe en dit betekent dat ook binnen de podotherapeutische praktijk deze patiëntencategorie vaker wordt gezien. De incidentie van bijwerkingen als een hand-voetsyndroom of een hand-voet-huidreactie hangt bij deze patiënten nauw samen met de middelen die gebruikt worden en de dosering van deze middelen binnen het oncologische behandeltraject. Maar wat moet je hier als podotherapeut over weten?

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Podosophia

Podosophia stelt zich ten doel de beroepsgroep van podotherapeuten te voorzien van informatie die nodig is voor het inhoudelijk uitoefenen van het vak en het voeren van de praktijk. Daarbij is ook rui ...

Literatuur
2.
go back to reference Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225–34. CrossRefPubMed Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225–34. CrossRefPubMed
3.
go back to reference Chen M, Chen J, Peng X, Xu Z, Shao J, Zhu Y, et al. The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environ Toxicol Pharmacol. 2017;49:81–8. CrossRefPubMed Chen M, Chen J, Peng X, Xu Z, Shao J, Zhu Y, et al. The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environ Toxicol Pharmacol. 2017;49:81–8. CrossRefPubMed
4.
go back to reference Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787–94. CrossRefPubMed Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787–94. CrossRefPubMed
5.
go back to reference Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica. 1974;148(2):90–2. CrossRefPubMed Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica. 1974;148(2):90–2. CrossRefPubMed
6.
go back to reference Hueso L, Sanmartín O, Nagore E, Botella-Estrada R, Requena C, Llombart B, et al. Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases. Actas Dermosifiliogr. 2008;99(4):281–90. CrossRefPubMed Hueso L, Sanmartín O, Nagore E, Botella-Estrada R, Requena C, Llombart B, et al. Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases. Actas Dermosifiliogr. 2008;99(4):281–90. CrossRefPubMed
7.
go back to reference Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, et al. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori. 2015;101(4):418–23. CrossRefPubMed Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, et al. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori. 2015;101(4):418–23. CrossRefPubMed
8.
go back to reference Hofheinz RD, Heinemann V, Weikersthal LF von, Laubender RP, Gencer D, Burkholder I, et al. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer. 2012;107(10):1678–83. CrossRefPubMedPubMedCentral Hofheinz RD, Heinemann V, Weikersthal LF von, Laubender RP, Gencer D, Burkholder I, et al. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer. 2012;107(10):1678–83. CrossRefPubMedPubMedCentral
9.
go back to reference Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, et al. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer. 2011;105(2):206–11. CrossRefPubMedPubMedCentral Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, et al. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer. 2011;105(2):206–11. CrossRefPubMedPubMedCentral
10.
go back to reference Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5‑fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X‑ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23(5):1190–7. CrossRefPubMed Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5‑fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X‑ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23(5):1190–7. CrossRefPubMed
11.
go back to reference Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998;16(3):1000–7. CrossRefPubMed Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998;16(3):1000–7. CrossRefPubMed
12.
go back to reference Samuels BL, Vogelzang NJ, Ruane M, Simon MA. Continuous venous infusion of doxorubicin in advanced sarcoma. Cancer Treat Rep. 1987;71:971–2. PubMed Samuels BL, Vogelzang NJ, Ruane M, Simon MA. Continuous venous infusion of doxorubicin in advanced sarcoma. Cancer Treat Rep. 1987;71:971–2. PubMed
13.
go back to reference O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–9. CrossRefPubMed O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–9. CrossRefPubMed
14.
go back to reference Sehouli J, Oskay-Ozcelik G, Kuhne J, Stengel D, Hindenburg HJ, Klare P, et al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol. 2006;17(6):957–61. CrossRefPubMed Sehouli J, Oskay-Ozcelik G, Kuhne J, Stengel D, Hindenburg HJ, Klare P, et al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol. 2006;17(6):957–61. CrossRefPubMed
15.
go back to reference Strauss HG, Hemsen A, Karbe I, Lautenschlager C, Persing M, Thomssen C. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anticancer Drugs. 2008;19(5):541–5. CrossRefPubMed Strauss HG, Hemsen A, Karbe I, Lautenschlager C, Persing M, Thomssen C. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anticancer Drugs. 2008;19(5):541–5. CrossRefPubMed
16.
go back to reference Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, et al. The hand-foot-syndrome associated with medical tumor therapy – classification and management. J Dtsch Dermatol Ges. 2010;8(9):652–61. PubMed Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, et al. The hand-foot-syndrome associated with medical tumor therapy – classification and management. J Dtsch Dermatol Ges. 2010;8(9):652–61. PubMed
17.
go back to reference Zimmerman GC, Keeling JH, Burris HA, Cook G, Irvin R, Kuhn J, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol. 1995;131(2):202–6. CrossRefPubMed Zimmerman GC, Keeling JH, Burris HA, Cook G, Irvin R, Kuhn J, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol. 1995;131(2):202–6. CrossRefPubMed
18.
go back to reference Gabra H, Cameron DA, Lee LE, Mackay J, Leonard RC. Weekly doxorubicin and continuous infusional 5‑fluorouracil for advanced breast cancer. Br J Cancer. 1996;74(12):2008–12. CrossRefPubMedPubMedCentral Gabra H, Cameron DA, Lee LE, Mackay J, Leonard RC. Weekly doxorubicin and continuous infusional 5‑fluorouracil for advanced breast cancer. Br J Cancer. 1996;74(12):2008–12. CrossRefPubMedPubMedCentral
19.
go back to reference Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-VEGF therapy. Clin Cancer Res. 2009;15(4):1411–6. CrossRefPubMedPubMedCentral Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-VEGF therapy. Clin Cancer Res. 2009;15(4):1411–6. CrossRefPubMedPubMedCentral
20.
go back to reference Chu D, Lacouture M, Fillos T, Wu S. Risk of hand-foot skin reaction with Sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47:176–86. CrossRefPubMed Chu D, Lacouture M, Fillos T, Wu S. Risk of hand-foot skin reaction with Sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47:176–86. CrossRefPubMed
21.
go back to reference Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–51. CrossRefPubMed Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–51. CrossRefPubMed
22.
go back to reference Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on Sorafenib and Sunitinib. Oncology. 2009;77(5):257–71. CrossRefPubMed Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on Sorafenib and Sunitinib. Oncology. 2009;77(5):257–71. CrossRefPubMed
23.
go back to reference Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557–66. CrossRefPubMed Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557–66. CrossRefPubMed
24.
go back to reference Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2013;31(3):787–97. CrossRefPubMed Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2013;31(3):787–97. CrossRefPubMed
25.
go back to reference Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2012;30(4):1773–81. CrossRefPubMed Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2012;30(4):1773–81. CrossRefPubMed
26.
go back to reference Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. CrossRefPubMed Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. CrossRefPubMed
27.
go back to reference Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691–7. CrossRefPubMed Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691–7. CrossRefPubMed
28.
go back to reference Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor Sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer. 2009;7(1):11–9. CrossRefPubMed Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor Sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer. 2009;7(1):11–9. CrossRefPubMed
29.
go back to reference Son H‑S, Lee WY, Lee W‑S, Yun SH, Chun H‑K. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving Capecitabine as adjuvant chemotherapy. Yonsei Med J. 2009;50(6):796–802. CrossRefPubMedPubMedCentral Son H‑S, Lee WY, Lee W‑S, Yun SH, Chun H‑K. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving Capecitabine as adjuvant chemotherapy. Yonsei Med J. 2009;50(6):796–802. CrossRefPubMedPubMedCentral
Metagegevens
Titel
Voetproblematiek bij een oncologisch behandeltraject
De rol van de podotherapeut bij de oncologische voet
Auteurs
Petra Renders
MSc Donja Lansink
Publicatiedatum
23-11-2018
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Podosophia / Uitgave 4/2018
Print ISSN: 0929-5380
Elektronisch ISSN: 1876-5815
DOI
https://doi.org/10.1007/s12481-018-0210-0